Modulation of Tumor Immune Microenvironment and Prognostic Value of Ferroptosis-Related Genes, and Candidate Target Drugs in Glioblastoma Multiforme
Pharmacology
0303 health sciences
Science & Technology
MUTATIONS
SIGNATURE
TEMOZOLOMIDE
BIOLOGY
RM1-950
ferroptosis
3. Good health
glioblastoma multiforme
03 medical and health sciences
multi-omics analysis
CELLS
SURVIVAL
IDH1
Pharmacology & Pharmacy
SENSITIZES GLIOBLASTOMA
prognosis
Therapeutics. Pharmacology
1115 Pharmacology and Pharmaceutical Sciences
Life Sciences & Biomedicine
PACKAGE
DOI:
10.3389/fphar.2022.898679
Publication Date:
2022-04-28T04:46:36Z
AUTHORS (15)
ABSTRACT
Glioblastoma multiforme (GBM) is the most common type of malignant brain tumor, among which IDH1-wild GBM has a poor prognosis. Recent studies have shown that ferroptosis-related genes (FRGs) are correlated with development and progression cancer. In GBM, role FRGs associated IDH1 status as biological indicators therapeutic targets remains to be clarified. Ten (STEAP3, HSPB1, MAP1LC3A, SOCS1, LOX, CAPG, CP, GDF15, CDKN1A, CD44) in were identified key through screening by survival analysis Random Forest using The Cancer Genome Atlas (TCGA) datasets, protein expressions verified. Transwell qPCR results showed ferroptosis promoted migration glioblastoma cells affected expression genes. Our study established prognostic model for patients based on ten different modeling method from previous study, GSVA algorithm. Further, we took methods functional enrichment analysis, clinical characteristics, immune cell infiltration, immunomodulator, ESTIMATE single nucleotide variant (SNV) molecular mechanisms strongly immune-related factors significantly involved p53 signaling pathway, senescence autophagy cancer, negative regulation kinase activity. Moreover, potential drugs Virtual Screening Molecular Docking. indicated novel ferrotosis-related possessed values.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (52)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....